FONT-SIZE Plus   Neg

Ligand Pharmaceuticals (LGND) Is Up Sharply Following FDA Approval

Ligand Pharmaceuticals (LGND: Quote) partner GlaxoSmithKline (GSK: Quote) announced Monday morning that the FDA approved PROMACTA for the treatment of thrombocytopenia in patients with chronic hepatitis C.

Ligand Pharmaceuticals has spiked to the upside following a slightly delayed opening and is currently higher by 2.61 at $19.28. The stock is now challenging the highs of the year, trading at a 3-month high.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Trade LGND now with 
Follow RTT